CompletedNCT02983188
Berberine for Antipsychotic-Related Metabolic Syndrome in Schizophrenia
About this title
Read the official source — NCT02983188Medication studyAges 18–65China
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- TuenmenSee all locations and recruitment
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateStarted: April 25, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 113
- Sponsor
- The University of Hong Kong
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- China
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT02983188
- Official title
Show the full official title
A Double-blind, Randomized, Placebo-controlled Trial of Berberine as an Adjuvant to Treat Antipsychotic-induced Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Tuenmen, Hong Kong · China
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is The University of Hong Kong, a university.
Did this study involve medication?
Yes. The study involved medication, including Berberine, Placebos and Antipsychotic Agents.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
